Renuvion Safely and Effectively Treats Lax Skin in Trial
In a Phase II study, the Renuvion device improved the appearance of lax skin in 82.5% of subjects after 6 months.
In a Phase II study, the Renuvion device improved the appearance of lax skin in 82.5% of subjects after 6 months.
Plastic surgeon Paul S. Kim, MD, discusses his role in the Renewing Lives campaign and how minimally invasive skin-tightening treatments like Renuvion are helping patients address post-weight loss skin laxity.
Incyte’s sNDA for ruxolitinib cream in children ages 2–11 now faces a new action date to allow additional data review.